BioTech 365

DECEMBER 30, 2020

Global Research Antibodies and Reagents Market Report 2020-2030: COVID-19 Growth and Change – Market is Expected to Stabilize and Reach $13.19

Reagent 40

Reagent Antibody Marketing Research 40

BioTech 365

DECEMBER 21, 2020

Global Antinuclear Antibody Testing Market Report 2020: Market to Reach $2.4 Billion by 2027 – Assay Kits & Reagents Expected to Account for $1.2 Billion – ResearchAndMarkets.com Global Antinuclear Antibody Testing Market Report 2020: Market to Reach $2.4 Billion by … Continue reading →

Reagent 40

Reagent Antibody Marketing 40

BioPharma Reporter

JULY 26, 2021

PerkinElmer will make the largest transaction in its history with the acquisition of Californiaâs BioLegend for $5.25bn.

Reagent 52

Reagent Antibody 52

BioTech 365

DECEMBER 22, 2020

LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.

Antibody 40

Antibody Reagent Life Science Research 40

BioTech 365

OCTOBER 20, 2020

CHICAGO & MUNICH–(BUSINESS WIRE)–#Antibodies–Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. … Continue reading →

Antibody 40

Antibody Reagent Manufacturing Marketing 40

BioTech 365

OCTOBER 7, 2020

Ten new monoclonal antibodies recognise distinct Spike protein epitopes on SARS-CoV-2 Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein Different epitopes support identification of matched-pair reagents for immunoassay development OXFORD, England–(BUSINESS WIRE)–The Native … (..)

Antibody 40

Antibody Reagent Protein Development 40

XTalks

OCTOBER 7, 2020

The innovative heat extraction process, which has sensitivity comparable to current extraction methods, captures viral particles directly, thereby eliminating the need for RNA extraction reagents to extract and concentrate viral RNA. This will help reduce both the materials and time required to complete molecular COVID-19 tests.

Reagent 98

Reagent RNA Life Science FDA Approval 98

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

pharmaphorum

OCTOBER 7, 2020

The company said the problems – which also include other items like reagents and screening kits – have resulted from a switch to a new warehouse, which ironically is intended to make production quicker and more efficient through the use of automated processes. Antibody test order.

Antibody 72

Antibody Reagent Production Doctors 72

Pharmaceutical Technology

SEPTEMBER 1, 2022

While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.

Manufacturing 130

Manufacturing Bacterium Reagent Production 130

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Reagent Pharma Companies Scientist 52

The Pharma Data

JANUARY 24, 2021

Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. .” Chris Bond , Ph.D., Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.

Engineer 52

Engineer Gene Editing Genome Genomics 52

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. MINNEAPOLIS , Oct. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

The Pharma Data

MARCH 13, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for lanadelumab subcutaneous injection, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE).

Drugs 52

Drugs Antibody Production Medicine 52

The Pharma Data

JULY 11, 2021

TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. All antibody titres were low. About TAKHZYRO ® (lanadelumab).

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

OCTOBER 19, 2020

Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Diagnostics.

Vaccine 52

Vaccine Vaccination Trials Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

The Biden team said it had identified 12 “immediate supply shortfalls” that have been critical to the pandemic response, including N95 surgical masks and isolation gowns, as well as swabs, reagents and pipettes used in testing, the Times reported. “We saw a knockout,” Moore said. “It was a scary result.”

Vaccine 52

Vaccine Vaccination Antibody Reagent 52

FDA Law Blog

FEBRUARY 23, 2025

FDA found that several changes to an in vitro diagnostic device could affect the safety or effectiveness of the device, including: Process change for IgM component that replaced monoclonal antibody product in a live animal with production in cell culture. Likewise, in a November 8, 2022 WL to Abbott Point of Care Ltd.,

Manufacturing 64

Manufacturing In-Vitro Reagent Production 64

XTalks

MARCH 11, 2025

Emerging evidence indicates that a multivalent mRNA vaccine encoding hemagglutinin antigens from all known influenza virus subtypes can elicit broad, cross-reactive antibody responses in animal models, demonstrating the potential of mRNA platforms to overcome challenges posed by antigenically variable viruses.

Vaccine 64

Vaccine Vaccination Development Manufacturing 64

The Pharma Data

JANUARY 21, 2021

The Biden team said it had identified 12 “immediate supply shortfalls” that have been critical to the pandemic response, including N95 surgical masks and isolation gowns, as well as swabs, reagents and pipettes used in testing, The New York Times reported. “We saw a knockout,” Moore said. “It was a scary result.”

Vaccine 52

Vaccine Vaccination Antibody Reagent 52